{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=9", "query": { "intervention": "antibody-drug conjugate", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:28:33.233Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01026233", "title": "Cardiac Safety Study of Brentuximab Vedotin (SGN-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-12-12", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026233" }, { "nct_id": "NCT07549412", "title": "A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Precemtabart tocentecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine/Tipiracil (FTD-TPI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1020, "start_date": "2026-05-06", "completion_date": "2029-10-16", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 19, "location_summary": "Lone Tree, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 16 more", "locations": [ { "city": "Lone Tree", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07549412" }, { "nct_id": "NCT05950945", "title": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2023-12-30", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Tampa, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950945" }, { "nct_id": "NCT05374512", "title": "A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 644, "start_date": "2022-05-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 27, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 23 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05374512" }, { "nct_id": "NCT01620229", "title": "Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic/Lymphoid Cancer" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2013-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01620229" }, { "nct_id": "NCT06039202", "title": "CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "CA102N", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Holy Stone Healthcare Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2027-12", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 1, "location_summary": "Gilbert, Arizona", "locations": [ { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06039202" }, { "nct_id": "NCT02020135", "title": "An Open-label Extension Study of PSMA ADC 2301 in mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "PSMA ADC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Progenics Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2013-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 6, "location_summary": "Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020135" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT06263543", "title": "Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Human Epidermal Growth Factor 2 Low Breast Cancer" ], "interventions": [ { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reshma L. Mahtani, D.O.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2024-06-17", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 3, "location_summary": "Miami, Florida • Atlanta, Georgia • Fairway, Kansas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06263543" }, { "nct_id": "NCT02874664", "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Rovalpituzumab Tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stemcentrx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2016-09", "completion_date": "2018-09-12", "has_results": false, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-10-14T17:28:33.233Z", "location_count": 13, "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02874664" } ] }